Inventor · disambiguated record
Katsunori Tsuboi
Also filed as: TSUBOI KATSUNORI
5 granted patents·6 pending applications·5 citations·filing 2005–2018
69Inventor score
Top patents by PatentIndex Score
11 records- 0172US9227962B2Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivativeDAINIPPON SUMITOMO PHARMA CO·Filed 2014·Granted Jan 5, 2016·1 cites·18 claims
- 0266US8471038B2Bicyclic heterocyclic compoundTSUBOI KATSUNORI·Filed 2009·Granted Jun 25, 2013·3 cites·40 claims
- 0362US9108930B2N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methodsCRAVATT BENJAMIN·Filed 2012·Granted Aug 18, 2015·1 cites·11 claims
- 0459US7879843B2Benzothiazin-3-one compound and intermediate thereforDAINIPPON SUMITOMO PHARMA CO·Filed 2009·Granted Feb 1, 2011·0 cites·7 claims
- 0559US2019241550A1Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivativeBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 0651US2016075697A1Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivativeBOSTON BIOMEDICAL INC·Filed 2015·Application pending·0 cites
- 0748US7598240B2Benzothiazin-3-one compound and intermediate thereforDAINIPPON SUMITOMO PHARMA CO·Filed 2005·Granted Oct 6, 2009·0 cites·8 claims
- 0848US2016031888A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2014·Application pending·0 cites
- 0947US2019241569A13-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerBOSTON BIOMEDICAL INC·Filed 2018·Application pending·0 cites
- 1043US2013303535A1Novel bicyclic heterocyclic compoundDAINIPPON SUMITOMO PHARMA CO·Filed 2013·Application pending·0 cites
- 1140US2009131412A1Novel 2-quinolone derivativeDAINIPPON SUMITOMO PHARMA CO·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Katsunori Tsuboi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →